Amylin Pharma is recently down 25c to $17.73 The FDA is expected to make a decision on the company's LAR (EQW-exenatide once weekly diabetes treatment) by March 5, 2010. February put option implied volatility is at 48, March puts are at 77, April is at 74; verses its 26-week average of 68 according to Track Data, suggesting larger March price movement. :theflyonthewall.com